Top

Current Hepatology Reports

Published in:

01-03-2018 | Management of Cirrhotic Patient (A Cardenas and P Tandon, Section Editors)

Clinical Impact of Depression in Cirrhosis

Authors: Joao Miguel Serigado, Katherine C. Barboza, Paula Marcus, Samuel H. Sigal

Published in: Current Hepatology Reports | Issue 1/2018

Abstract

Purpose of Review

Depression is the most commonly diagnosed psychiatric illness. It is prevalent in most chronic medical conditions and is associated with increased morbidity and mortality. Depression is especially common in patients with cirrhosis.

Recent Findings

In this review, we discuss the prevalence, risk factors, diagnosis, clinical impact, and treatment of depression in cirrhosis. We describe various screening tests important for diagnosis, the interaction of depression with hepatic encephalopathy, and its significant impact on medication adherence, mortality, and caregiver burden.

Summary

These findings highlight the importance of appropriate screening, diagnosis, and treatment of depression in patients with cirrhosis.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders FED-, American Psychiatric Association, Arlington 2013.

Hatou K. Mental Health Atlas 2011 (WHO). Seishin Shinkeigaku Zasshi. 2014;116:267.PubMed

Harter M, Baumeister H, Reuter K, et al. Increased 12-month prevalence rates of mental disorders in patients with chronic somatic diseases. Psychother Psychosom. 2007;76:354–60.PubMedCrossRef

Katon W, Lin EH, Kroenke K. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry. 2007;29(2):147–55. https://doi.org/10.1016/j.genhosppsych.2006.11.005.PubMedCrossRef

Baumeister H, Hutter N, Bengel J, et al. Quality of life in medically ill persons with comorbid mental disorders: a systematic review and meta-analysis. Psychother Psychosom. 2011;80:275–86.PubMedCrossRef

Cuijpers P, Smit F. Excess mortality in depression: a meta-analysis of community studies. J Affect Disord. 2002;72(3):227–36. https://doi.org/10.1016/S0165-0327(01)00413-X.PubMedCrossRef

Rihmer Z, Gonda X. Prevention Of depression-related suicides in primary care. Psychiatr Hung. 2012;27:72–81.PubMed

Malone KM, Haas GL, Sweeney JA, Mann JJ. Major depression and the risk of attempted suicide. J Affect Disord. 1995;34(3):173–85. https://doi.org/10.1016/0165-0327(95)00015-F.PubMedCrossRef

Moussavi S, Chatterji S, Verdes E, et al. Depression, chronic diseases, and decrements in health: results from the world health surveys. Lancet. 2007;370:851–8.PubMedCrossRef

10.

Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med. 2004;66(6):802–13. https://doi.org/10.1097/01.psy.0000146332.53619.b2.PubMedCrossRef

11.

Satin JR, Linden W, Phillips MJ. Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer. 2009;115(22):5349–61. https://doi.org/10.1002/cncr.24561.PubMedCrossRef

12.

Berkman LF, Blumenthal J, Burg M, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA. 2003;289:3106–16.PubMedCrossRef

13.

Evidence PWF. Report on the occurrence, assessment, and treatment of depression in cancer patients. J Natl Cancer Inst Monogr. 2004:32–9.

14.

Bianchi G, Marchesini G, Nicolino F, et al. Psychological status and depression in patients with liver cirrhosis. Dig Liver Dis. 2005;37:593–600.PubMedCrossRef

15.

Le Strat Y, Le Foll B, Dubertret C. major Depression and suicide attempts in patients with liver disease in the United States. Liver Int. 2015;35(7):1910–6. https://doi.org/10.1111/liv.12612.PubMedCrossRef

16.

Weinstein AA, Kallman Price J, Stepanova M, et al. Depression in patients with nonalcoholic fatty liver disease and chronic viral hepatitis B and C. Psychosomatics. 2011;52:127–32.PubMedCrossRef

17.

•• Nardelli S, Pentassuglio I, Pasquale C, et al. Depression, anxiety and alexithymia symptoms are major determinants of health related quality of life (HRQoL) in cirrhotic patients. Metab Brain Dis. 2013;28:239–43. This study compared the impact of factors such as depression, mood, hepatic encephalopathy, severity of cirrhosis or presence of hepatocellular caricoma in the quality of life. Correlation was observed between results in psychological test scores and quality of life scores, but not correlated with disease severity.PubMedCrossRef

18.

Zhu HP, Gu YR, Zhang GL, et al. Depression in patients with chronic hepatitis B and cirrhosis is closely associated with the severity of liver cirrhosis. Exp Ther Med. 2016;12(1):405–9. https://doi.org/10.3892/etm.2016.3271.PubMedPubMedCentralCrossRef

19.

Youssef NA, Abdelmalek MF, Binks M, Guy CD, Omenetti A, Smith AD, et al. Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease. Liver Int. 2013;33(7):1062–70. https://doi.org/10.1111/liv.12165.PubMedCrossRef

20.

Leutscher PD, Lagging M, Buhl MR, et al. Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology. 2010;52:430–5.PubMedCrossRef

21.

Marmorstein NR. Longitudinal associations between alcohol problems and depressive symptoms: early adolescence through early adulthood. Alcohol Clin Exp Res. 2009;33(1):49–59. https://doi.org/10.1111/j.1530-0277.2008.00810.x.PubMedCrossRef

22.

Swendsen JD, Merikangas KR, Canino GJ, Kessler RC, Rubio-Stipec M, Angst J. The comorbidity of alcoholism with anxiety and depressive disorders in four geographic communities. Compr Psychiatry. 1998;39(4):176–84. https://doi.org/10.1016/S0010-440X(98)90058-X.PubMedCrossRef

23.

van Os E, van den Broek WW, Mulder PG, ter Borg PC, Bruijn JA, van Buuren HR. Depression in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol. 2007;46(6):1099–103. https://doi.org/10.1016/j.jhep.2007.01.036.PubMedCrossRef

24.

Tillmann HL, Wiese M, Braun Y, et al. Quality of life in patients with various liver diseases: patients with HCV show greater mental impairment, while patients with PBC have greater physical impairment. J Viral Hepat. 2011;18:252–61.PubMedCrossRef

25.

Wilson MP, Castillo EM, Batey AM, Sapyta J, Aronson S. Hepatitis C and depressive symptoms: psychological and social factors matter more than liver injury. Int J Psychiatry Med. 2010;40(2):199–215. https://doi.org/10.2190/PM.40.2.f.PubMedCrossRef

26.

DiMartini A, Dew MA, Javed L, et al. Pretransplant psychiatric and medical comorbidity of alcoholic liver disease patients who received liver transplant. Psychosomatics. 2004;45(6):517–23. https://doi.org/10.1176/appi.psy.45.6.517.PubMedCrossRef

27.

Xu H, Zhou Y, Ko F, Ping J, Zhang J, Zhao C, et al. Female gender and gastrointestinal symptoms, not brain-derived neurotrophic factor, are associated with depression and anxiety in cirrhosis. Hepatol Res. 2017;47(3):E64–73. https://doi.org/10.1111/hepr.12723.PubMedCrossRef

28.

Perng CL, Shen CC, Hu LY, Yeh CM, Chen MH, Tsai CF, et al. Risk of depressive disorder following non-alcoholic cirrhosis: a nationwide population-based study. PLoS One. 2014;9(2):e88721. https://doi.org/10.1371/journal.pone.0088721.PubMedPubMedCentralCrossRef

29.

Stewart CA, Enders FT, Mitchell MM, et al. The cognitive profile of depressed patients with cirrhosis. Prim Care Companion CNS Disord. 2011;13

30.

Fritz E, Hammer J. Gastrointestinal symptoms in patients with liver cirrhosis are linked to impaired quality of life and psychological distress. Eur J Gastroenterol Hepatol. 2009;21(4):460–5. https://doi.org/10.1097/MEG.0b013e328318ed19.PubMedCrossRef

31.

Vaughn-Sandler V, Sherman C, Aronsohn A, et al. Consequences of perceived stigma among patients with cirrhosis. Dig Dis Sci. 2014;59:681–6.PubMedCrossRef

32.

Ko FY, Tsai SJ, Yang AC, Zhou Y, Xu LM. Association of CD8 T cells with depression and anxiety in patients with liver cirrhosis. Int J Psychiatry Med. 2013;45(1):15–29. https://doi.org/10.2190/PM.45.1.b.PubMedCrossRef

33.

Loftis JM, Huckans M, Ruimy S, et al. Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1beta and tumor necrosis factor-alpha. Neurosci Lett. 2008;430:264–8.PubMedCrossRef

34.

Rogal SS, Bielefeldt K, Wasan AD, et al. Inflammation, psychiatric symptoms, and opioid use are associated with pain and disability in patients with cirrhosis. Clin Gastroenterol Hepatol. 2015;13:1009–16.PubMedCrossRef

35.

Lopez-Navas A, Rios A, Moya-Faz FJ, et al. Emotional-type psychopathologic symptoms among patients with terminal chronic alcohol-induced liver cirrhosis. Transplant Proc. 2012;44:1510–2.PubMedCrossRef

36.

Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in primary care: a meta-analysis. Lancet. 2009;374(9690):609–19. https://doi.org/10.1016/S0140-6736(09)60879-5.PubMedCrossRef

37.

Pignone MP, Gaynes BN, Rushton JL, Burchell CM, Orleans CT, Mulrow CD, et al. Screening for depression in adults: a summary of the evidence for the U.S. preventive services task force. Ann Intern Med. 2002;136(10):765–76. https://doi.org/10.7326/0003-4819-136-10-200205210-00013.PubMedCrossRef

38.

Kroenke K, Spitzer RL, Williams JB, et al. The patient health questionnaire somatic, anxiety, and depressive symptom scales: a systematic review. Gen Hosp Psychiatry. 2010;32(4):345–59. https://doi.org/10.1016/j.genhosppsych.2010.03.006.PubMedCrossRef

39.

Huang FY, Chung H, Kroenke K, et al. Using the patient health Questionnaire-9 to measure depression among racially and ethnically diverse primary care patients. J Gen Intern Med. 2006;21:547–52.PubMedPubMedCentralCrossRef

40.

Malpass A, Shaw A, Kessler D, et al. Concordance between PHQ-9 scores and patients' experiences of depression: a mixed methods study. Br J Gen Pract. 2010;60:e231–8.PubMedPubMedCentralCrossRef

41.

Li C, Friedman B, Conwell Y, et al. Validity of the patient health questionnaire 2 (PHQ-2) in identifying major depression in older people. J Am Geriatr Soc. 2007;55:596–602.PubMedCrossRef

42.

Arroll B, Goodyear-Smith F, Crengle S, et al. Validation of PHQ-2 and PHQ-9 to screen for major depression in the primary care population. Ann Fam Med. 2010;8:348–53.PubMedPubMedCentralCrossRef

43.

Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4(6):561–71. https://doi.org/10.1001/archpsyc.1961.01710120031004.PubMedCrossRef

44.

Beck AT, Guth D, Steer RA, et al. Screening for major depression disorders in medical inpatients with the Beck depression inventory for primary care. Behav Res Ther. 1997;35:785–91.PubMedCrossRef

45.

Maldonado JR, Dubois HC, David EE, Sher Y, Lolak S, Dyal J, et al. The Stanford integrated psychosocial assessment for transplantation (SIPAT): a new tool for the psychosocial evaluation of pre-transplant candidates. Psychosomatics. 2012;53(2):123–32. https://doi.org/10.1016/j.psym.2011.12.012.PubMedCrossRef

46.

Maldonado JR, Sher Y, Lolak S, et al. The Stanford integrated psychosocial assessment for transplantation: a prospective study of medical and psychosocial outcomes. Psychosom Med. 2015;77:1018–30.PubMedCrossRef

47.

Hilsabeck RC, Hassanein TI, Perry W. Biopsychosocial predictors of fatigue in chronic hepatitis C. J Psychosom Res. 2005;58(2):173–8. https://doi.org/10.1016/j.jpsychores.2004.07.003.PubMedCrossRef

48.

Huet PM, Deslauriers J, Tran A, et al. Impact of fatigue on the quality of life of patients with primary biliary cirrhosis. Am J Gastroenterol. 2000;95:760–7.PubMedCrossRef

49.

Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371(9615):838–51. https://doi.org/10.1016/S0140-6736(08)60383-9.PubMedPubMedCentralCrossRef

50.

•• Barboza KC, Salinas LM, Sahebjam F, et al. Impact of depressive symptoms and hepatic encephalopathy on health-related quality of life in cirrhotic hepatitis C patients. Metab Brain Dis. 2016;31:869–80. This study investigates the impact of hepatic encephalopathy and depression in the quality of life of patients with cirrhosis, and calculate that the impact of these two conditions accounts for 68% of the variability observed in differences in quality of life PubMedCrossRef

51.

Bajaj JS, Thacker LR, Heuman DM, Sterling RK, Stravitz RT, Sanyal AJ, et al. Cognitive performance as a predictor of hepatic encephalopathy in pretransplant patients with cirrhosis receiving psychoactive medications: a prospective study. Liver Transpl. 2012;18(10):1179–87. https://doi.org/10.1002/lt.23484.PubMedPubMedCentralCrossRef

52.

Rossi D, Galant LH, Marroni CA. Reliability of the Fatigue Severity Scale in Cirrhotic and Correlation with Depression and Quality of Life: preliminary assessment. Arq Gastroenterol. 2016;53(3):203–5. https://doi.org/10.1590/S0004-28032016000300015.PubMedCrossRef

53.

Kalaitzakis E, Josefsson A, Castedal M, et al. Factors related to fatigue in patients with cirrhosis before and after liver transplantation. Clin Gastroenterol Hepatol. 2012;10:174–81. 181 e1PubMedCrossRef

54.

Girgrah N, Reid G, MacKenzie S, et al. Cirrhotic cardiomyopathy: does it contribute to chronic fatigue and decreased health-related quality of life in cirrhosis? Can J Gastroenterol. 2003;17:545–51.PubMedCrossRef

55.

Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.PubMedCrossRef

56.

Bajaj JS, Thacker LR, Wade JB, Sanyal AJ, Heuman DM, Sterling RK, et al. PROMIS computerised adaptive tests are dynamic instruments to measure health-related quality of life in patients with cirrhosis. Aliment Pharmacol Ther. 2011;34(9):1123–32. https://doi.org/10.1111/j.1365-2036.2011.04842.x.PubMedPubMedCentralCrossRef

57.

Saab S, Ibrahim AB, Shpaner A, Younossi ZM, Lee C, Durazo F, et al. MELD fails to measure quality of life in liver transplant candidates. Liver Transpl. 2005;11(2):218–23. https://doi.org/10.1002/lt.20345.PubMedCrossRef

58.

Kanwal F, Hays RD, Kilbourne AM, Dulai GS, Gralnek IM. Are physician-derived disease severity indices associated with health-related quality of life in patients with end-stage liver disease? Am J Gastroenterol. 2004;99(9):1726–32. https://doi.org/10.1111/j.1572-0241.2004.30300.x.PubMedCrossRef

59.

Younossi ZM, Boparai N, Price LL, et al. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol. 2001;96:2199–205.PubMedCrossRef

60.

Marchesini G, Bianchi G, Amodio P, et al. Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology. 2001;120:170–8.PubMedCrossRef

61.

Hauser W, Holtmann G, Grandt D. Determinants of health-related quality of life in patients with chronic liver diseases. Clin Gastroenterol Hepatol. 2004;2(2):157–63. https://doi.org/10.1016/S1542-3565(03)00315-X.PubMedCrossRef

62.

Tsai CF, Chu CJ, Wang YP, Liu PY, Huang YH, Lin HC, et al. Increased serum interleukin-6, not minimal hepatic encephalopathy, predicts poor sleep quality in nonalcoholic cirrhotic patients. Aliment Pharmacol Ther. 2016;44(8):836–45. https://doi.org/10.1111/apt.13765.PubMedCrossRef

63.

Cordoba J, Cabrera J, Lataif L, et al. High prevalence of sleep disturbance in cirrhosis. Hepatology. 1998;27:339–45.PubMedCrossRef

64.

Montagnese S, Middleton B, Skene DJ, et al. Night-time sleep disturbance does not correlate with neuropsychiatric impairment in patients with cirrhosis. Liver Int. 2009;29:1372–82.PubMedCrossRef

65.

Mostacci B, Ferlisi M, Baldi Antognini A, et al. Sleep disturbance and daytime sleepiness in patients with cirrhosis: a case control study. Neurol Sci. 2008;29:237–40.PubMedCrossRef

66.

Seraj SM, Campbell EJ, Argyropoulos SK, Wegermann K, Chung RT, Richter JM. Hospital readmissions in decompensated cirrhotics: factors pointing toward a prevention strategy. World J Gastroenterol. 2017;23(37):6868–76. https://doi.org/10.3748/wjg.v23.i37.6868.PubMedPubMedCentralCrossRef

67.

Morales BP, Planas R, Bartoli R, et al. Early hospital readmission in decompensated cirrhosis: incidence, impact on mortality, and predictive factors. Dig Liver Dis. 2017;49:903–9.PubMedCrossRef

68.

Acharya C, Betrapally NS, Gillevet PM, Sterling RK, Akbarali H, White MB, et al. Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis. Aliment Pharmacol Ther. 2017;45(2):319–31. https://doi.org/10.1111/apt.13858.PubMedCrossRef

69.

Scaglione SJ, Metcalfe L, Kliethermes S, et al. Early hospital readmissions and mortality in patients with decompensated cirrhosis enrolled in a large National Health Insurance Administrative Database. J Clin Gastroenterol. 2017;51:839–44.PubMed

70.

Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333(7557):15–0. https://doi.org/10.1136/bmj.38875.675486.55.PubMedPubMedCentralCrossRef

71.

Currie CJ, Peyrot M, Morgan CL, et al. The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care. 2012;35:1279–84.PubMedPubMedCentralCrossRef

72.

Hayward KL, Valery PC, Martin JH, Karmakar A, Patel PJ, Horsfall LU, et al. Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis. World J Gastroenterol. 2017;23(40):7321–31. https://doi.org/10.3748/wjg.v23.i40.7321.PubMedPubMedCentralCrossRef

73.

Kuo SZ, Haftek M, Lai JC. Factors associated with medication non-adherence in patients with end-stage liver disease. Dig Dis Sci. 2017;62(2):543–9. https://doi.org/10.1007/s10620-016-4391-z.PubMedCrossRef

74.

• Bajaj JS, Reddy KR, Tandon P, et al. The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. Hepatology. 2016;64:200–8. This study evaluates the determinats of 3-month readmission in patients with cirrhosis. Patients with worse MELD score, on prophylactic antibiotics, and those with prior hepatic encephalopathy were identified as a high-risk group for readmission PubMedPubMedCentralCrossRef

75.

Leevy CB, Phillips JA. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci. 2007;52(3):737–41. https://doi.org/10.1007/s10620-006-9442-4.PubMedCrossRef

76.

Polis S, Zang L, Mainali B, et al. Factors associated with medication adherence in patients living with cirrhosis. J Clin Nurs. 2016;25:204–12.PubMedCrossRef

77.

Evaluation SS. Of the impact of rehospitalization in the management of hepatic encephalopathy. Int J Gen Med. 2015;8:165–73.

78.

Morales BP, Planas R, Bartoli R, et al. Hepacontrol. A program that reduces early readmissions, mortality at 60 days, and healthcare costs in decompensated cirrhosis. Dig Liver Dis. 2017;

79.

Tapper EB, Finkelstein D, Mittleman MA, et al. A quality improvement initiative reduces 30-day rate of readmission for patients with cirrhosis. Clin Gastroenterol Hepatol. 2016;14:753–9.PubMedCrossRef

80.

Burge S, White D, Bajorek E, et al. Correlates of medication knowledge and adherence: findings from the residency research network of South Texas. Fam Med. 2005;37:712–8.PubMed

81.

Huang CJ, Hsieh HM, Chiu HC, Wang PW, Lee MH, Li CY, et al. Health care utilization and expenditures of patients with diabetes comorbid with depression disorder: a National Population-Based Cohort Study. Psychiatry Investig. 2017;14(6):770–8. https://doi.org/10.4306/pi.2017.14.6.770.PubMedPubMedCentralCrossRef

82.

Hennein R, Hwang SJ, Au R, Levy D, Muntner P, Fox CS, et al. Barriers to medication adherence and links to cardiovascular disease risk factor control: the Framingham heart study. Intern Med J. 2017; https://doi.org/10.1111/imj.13687.

83.

Xie J, Deng W. Psychosocial intervention for patients with type 2 diabetes mellitus and comorbid depression: a meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat. 2017;13:2681–90. https://doi.org/10.2147/NDT.S116465.PubMedPubMedCentralCrossRef

84.

Hayward KL, Martin JH, Cottrell WN, Karmakar A, Horsfall LU, Patel PJ, et al. Patient-oriented education and medication management intervention for people with decompensated cirrhosis: study protocol for a randomized controlled trial. Trials. 2017;18(339):339. https://doi.org/10.1186/s13063-017-2075-4.PubMedPubMedCentralCrossRef

85.

Rogal SS, Udawatta V, Akpan I, et al. Risk factors for hospitalizations among patients with cirrhosis: a prospective cohort study. PLoS One. 2017;12:e0187176.PubMedPubMedCentralCrossRef

86.

Nguyen DL, Chao D, Ma G, et al. Quality of life and factors predictive of burden among primary caregivers of chronic liver disease patients. Ann Gastroenterol. 2015;28:124–9.PubMedPubMedCentral

87.

Bajaj JS, Wade JB, Gibson DP, Heuman DM, Thacker LR, Sterling RK, et al. The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol. 2011;106(9):1646–53. https://doi.org/10.1038/ajg.2011.157.PubMedPubMedCentralCrossRef

88.

Goetzinger AM, Blumenthal JA, O'Hayer CV, et al. Stress and coping in caregivers of patients awaiting solid organ transplantation. Clin Transpl. 2012;26(1):97–104. https://doi.org/10.1111/j.1399-0012.2011.01431.x.CrossRef

89.

Bajaj JS, Riggio O, Allampati S, et al. Cognitive dysfunction is associated with poor socioeconomic status in patients with cirrhosis: an international multicenter study. Clin Gastroenterol Hepatol. 2013;11:1511–6.PubMedCrossRef

90.

Miyazaki ET, Dos Santos R Jr, Miyazaki MC, et al. Patients on the waiting list for liver transplantation: caregiver burden and stress. Liver Transpl. 2010;16(10):1164–8. https://doi.org/10.1002/lt.22130.PubMedCrossRef

91.

Dominguez-Cabello E, Perez-San-Gregorio MA, Martin-Rodriguez A, et al. Comparison of anxious and depressive symptomatology among pretransplant hepatic patients and their relatives. Transplant Proc. 2010;42(8):2962–3. https://doi.org/10.1016/j.transproceed.2010.07.058.PubMedCrossRef

92.

Russ TC, Kivimaki M, Morling JR, et al. Association between psychological distress and liver disease mortality: a meta-analysis of individual study participants. Gastroenterology. 2015;148(5):958–66 e4. https://doi.org/10.1053/j.gastro.2015.02.004.PubMedCrossRef

93.

Singh N, Gayowski T, Wagener MM, et al. Depression in patients with cirrhosis. Impact on outcome. Dig Dis Sci. 1997;42:1421–7.PubMedCrossRef

94.

DiMartini A, Dew MA, Chaiffetz D, Fitzgerald MG, deVera ME, Fontes P. Early trajectories of depressive symptoms after liver transplantation for alcoholic liver disease predicts long-term survival. Am J Transplant. 2011;11(6):1287–95. https://doi.org/10.1111/j.1600-6143.2011.03496.x.PubMedPubMedCentralCrossRef

95.

Corruble E, Barry C, Varescon I, et al. Depressive symptoms predict long-term mortality after liver transplantation. J Psychosom Res. 2011;71:32–7.PubMedCrossRef

96.

Rogal SS, Dew MA, Fontes P, DiMartini AF. Early treatment of depressive symptoms and long-term survival after liver transplantation. Am J Transplant. 2013;13(4):928–35. https://doi.org/10.1111/ajt.12164.PubMedPubMedCentralCrossRef

97.

Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis - a practical guide. Aliment Pharmacol Ther. 2013;37(12):1132–56. https://doi.org/10.1111/apt.12324.PubMedCrossRef

98.

Food and Drug Administration. Guidance for industry: Pharmacokinetics in patients with impaired hepatic: study design, data analysis, and impact on dosing and labeling. Accessed from https://http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072123.pdf on September 14 2017.

99.

European Medicines Agency. Guideline on the evaluation of the Pharmacokinetics of medicinal products in patients with impaired hepatic function. Accessed from http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003122.pdf on September 14 2017.

100.

Mullish BH, Kabir MS, Thursz MR, Dhar A. Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation. Aliment Pharmacol Ther. 2014;40(8):880–92. https://doi.org/10.1111/apt.12925.PubMedCrossRef

101.

Crone CC, Gabriel GM, DiMartini A. An overview of psychiatric issues in liver disease for the consultation-liaison psychiatrist. Psychosomatics. 2006;47(3):188–205. https://doi.org/10.1176/appi.psy.47.3.188.PubMedCrossRef

102.

Crone CC, Gabriel GM. Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations. Clin Pharmacokinet. 2004;43(6):361–94. https://doi.org/10.2165/00003088-200443060-00002.PubMedCrossRef

103.

Franz CC, Egger S, Born C, Rätz Bravo AE, Krähenbühl S. Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis. Eur J Clin Pharmacol. 2012;68(2):179–88. https://doi.org/10.1007/s00228-011-1105-5.PubMedCrossRef

104.

Mayo MJ, Handem I, Saldana S, et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology. 2007;45:666–74.PubMedCrossRef

105.

Joffe P, Larsen FS, Pedersen V, Ring-Larsen H, Aaes-Jørgensen T, Sidhu J. Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. Eur J Clin Pharmacol. 1998;54(3):237–42. https://doi.org/10.1007/s002280050452.PubMedCrossRef

106.

Areberg J, Christophersen JS, Poulsen MN, Larsen F, Molz KH. The pharmacokinetics of escitalopram in patients with hepatic impairment. AAPS J. 2006;8(1):E14–9. https://doi.org/10.1208/aapsj080102.PubMedPubMedCentralCrossRef

107.

Demolis JL, Angebaud P, Grange JD, et al. Influence of liver cirrhosis on sertraline pharmacokinetics. Br J Clin Pharmacol. 1996;42:394–7.PubMedPubMedCentralCrossRef

108.

Bergstrom RF, Beasley CM Jr, Levy NB, et al. The effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and risk-benefit profile of fluoxetine. Int Clin Psychopharmacol. 1993;8(4):261–6. https://doi.org/10.1097/00004850-199300840-00009.PubMedCrossRef

109.

Andrade C, Sandarsh S, Chethan KB, et al. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry. 2010;71:1565–75.PubMedCrossRef

110.

Skop BP, Brown TM. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics. 1996;37(1):12–6. https://doi.org/10.1016/S0033-3182(96)71592-X.PubMedCrossRef

111.

Weinrieb RM, Auriacombe M, Lynch KG, et al. A critical review of selective serotonin reuptake inhibitor-associated bleeding: balancing the risk of treating hepatitis C-infected patients. J Clin Psychiatry. 2003;64:1502–10.PubMedCrossRef

112.

MacGillivray S, Arroll B, Hatcher S, et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ. 2003;326:1014.PubMedPubMedCentralCrossRef

113.

Hrdina PD, Lapierre YD, Koranyi EK. Altered amitriptyline kinetics in a depressed patient with porto-caval anastomosis. Can J Psychiatr. 1985;30(2):111–3. https://doi.org/10.1177/070674378503000205.CrossRef

114.

DeVane CL, Laizure SC, Stewart JT, et al. Disposition of bupropion in healthy volunteers and. Subjects with Alcoholic Liver Disease J Clin Psychopharmacol. 1990;10:328-32.PubMed

115.

Ascher JA, Cole JO, Colin JN, et al. bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995;56(9):395–401.PubMed

116.

Livingston MG, Livingston HM. Monoamine oxidase inhibitors. An update on drug interactions. Drug Saf. 1996;14(4):219–27.PubMedCrossRef

117.

Alam A, Voronovich Z, Carley JA. A review of therapeutic uses of mirtazapine in psychiatric and medical conditions. Prim Care Companion CNS Disord. 2013;15

118.

Hui CK, Yuen MF, Wong WM, et al. Mirtazapine-induced hepatotoxicity. J Clin Gastroenterol. 2002;35(3):270–1. https://doi.org/10.1097/00004836-200209000-00014.PubMedCrossRef

119.

Horsmans Y, De Clercq M, Sempoux C. Venlafaxine-associated hepatitis. Ann Intern Med. 1999;130(11):944. https://doi.org/10.7326/0003-4819-130-11-199906010-00014.PubMedCrossRef

120.

Cardona X, Avila A, Castellanos P. Venlafaxine-associated hepatitis. Ann Intern Med. 2000;132(5):417. https://doi.org/10.7326/0003-4819-132-5-200003070-00016.PubMedCrossRef

121.

Montagnese S, De Pitta C, De Rui M, et al. Sleep-wake abnormalities in patients with cirrhosis. Hepatology. 2014;59:705–12.PubMedCrossRef

122.

Llorca PM, Spadone C, Sol O, et al. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. J Clin Psychiatry. 2002;63:1020–7.PubMedCrossRef

123.

Wong J, Motulsky A, Abrahamowicz M, et al. Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system. BMJ. 2017;356:j603.PubMedPubMedCentralCrossRef

124.

Camargos EF, Louzada LL, Quintas JL, Naves JOS, Louzada FM, Nóbrega OT. Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study. Am J Geriatr Psychiatry. 2014;22(12):1565–74. https://doi.org/10.1016/j.jagp.2013.12.174.PubMedCrossRef

125.

Stokes CS, Grunhage F, Baus C, et al. Vitamin D supplementation reduces depressive symptoms in patients with chronic liver disease. Clin Nutr. 2016;35:950–7.PubMedCrossRef

126.

Epstein-Lubow GP, Miller IW, McBee L. Mindfulness training for caregivers. Psychiatr Serv. 2006;57(3):421. https://doi.org/10.1176/appi.ps.57.3.421.PubMedCrossRef

127.

Bowen S, Witkiewitz K, Dillworth TM, et al. Mindfulness meditation and substance use in an incarcerated population. Psychol Addict Behav. 2006;20:343–7.PubMedCrossRef

128.

Mantzios M, Wilson JC. Mindfulness, eating Behaviours, and obesity: a review and reflection on current findings. Curr Obes Rep. 2015;4(1):141–6. https://doi.org/10.1007/s13679-014-0131-x.PubMedCrossRef

129.

Ludwig DS, Kabat-Zinn J. Mindfulness in medicine. JAMA. 2008;300:1350–2.PubMedCrossRef

130.

• Bajaj JS, Ellwood M, Ainger T, et al. Mindfulness-Based Stress Reduction Therapy Improves Patient and Caregiver-Reported Outcomes in Cirrhosis. Clin Transl Gastroenterol. 2017;8:e108. In this article Bajaj et al investigate a novel treatment approach to depression in patients with cirrhosis. The study showed promising results with improvement in depression and quality of life scores in both patients and caregivers PubMedPubMedCentralCrossRef

131.

Ramirez P, Febrero B, Martinez-Alarcon L, et al. Benefits of group psychotherapy in cirrhotic patients on the liver transplant waiting list. Transplant Proc. 2015;47:2382–4.PubMedCrossRef

132.

Marcus P. Integrating behavioral health into a transplantation service-one Institution's approach. Curr Psychiatr Rev. 2017;13(1) https://doi.org/10.2174/1573400513666161108105410.

133.

Baumann AJ, Wheeler DS, James M, Turner R, Siegel A, Navarro VJ. Benefit of early palliative care intervention in end-stage liver disease patients awaiting liver transplantation. J Pain Symptom Manag. 2015;50(6):882–6 e2. https://doi.org/10.1016/j.jpainsymman.2015.07.014.CrossRef

Title: Clinical Impact of Depression in Cirrhosis
Authors: Joao Miguel Serigado
Katherine C. Barboza
Paula Marcus
Samuel H. Sigal
Publication date: 01-03-2018
Publisher: Springer US
Published in: Current Hepatology Reports / Issue 1/2018
Electronic ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-018-0386-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 1/2018

Assessment and Management of Sleep Disturbance in Cirrhosis

The Assessment and Management of Pain in Cirrhosis

Early Integration of Advance Care Planning (ACP) into Cirrhosis Care: Why We Need It

Tackling 30-Day Readmissions in Patients with Cirrhosis

End-Stage Renal Disease and Treatment of Hepatitis C Virus Infection

Ethical Issues in Patients with Cirrhosis

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage